SecBot SecBot

STLN

Starling Oncology, Inc.
Nasdaq· CIK 0001799191 Biotech & Drug Discovery
$6.54 +0.25 (+3.97%)
Oct 27 4:00 PM ET · prev $6.29
Market cap
$683.9M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$9.00
+38% · range $8.00–11.00
Next earnings
Nov 11
in 15 days
1 year
+41.9%
from $4.61 · Oct 27
30 days
−1.5%
from $6.64
52-week range
$2.38–7.05
−7% from high · low Feb 12
Avg volume 20D
1.18M
shares / day
Short interest
🔒 Subscribers only
Insider net
−$1.9M
1 buyer · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/3 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Two insiders at Starling Oncology traded in opposite directions within a week: Director Brad Hively sold…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $78.5K at an average $6.54. 2 insiders sold $1.9M.

  • InstitutionsBULLISH

    Q2 2026: 23 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • TrendRANGE

    1% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GOLDMAN SACHS GROUP INCADD1,735,337$9.4M
Nuveen, LLCDOUBLED1,408,720$7.6M
RENAISSANCE TECHNOLOGIES LLCADD1,365,913$7.4M
MARSHALL WACE, LLPDOUBLED1,222,498$6.6M
CITADEL ADVISORS LLCADD894,101$4.9M
JANE STREET GROUP, LLCDOUBLED852,163$4.6M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPADD710,888$3.9M
BANK OF AMERICA CORP /DE/DOUBLED391,997$2.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy3Buy7Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +38%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026Needham
MAINTAIN
MAINTAINBuy
Jul 9, 2026BTIG
MAINTAIN
MAINTAINBuy
Jul 6, 2026Lake Street
INITIATE
INITIATEBuy
Jun 17, 2026Needham
MAINTAIN
MAINTAINBuy
Jun 8, 2026BTIG
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$78.5K
bought · 1 insider
$1.9M
sold · 2 insiders
−0.0%
vs their $6.54 cost
DateInsiderTypeValue
Aug 21, 2026
Hively Brad
Director
SELL$1.9M
Aug 14, 2026
Chernett Jorey
10%+ Owner
BUY$78.5K
Aug 13, 2026
Chernett Jorey
10%+ Owner
SELL$624.00

Earnings setup

Estimates
Nov 11
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Earnings
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN)
Sep 1, 2026 SEC
Brad Hively, Vice Chairman of the Board, notified Starling Oncology of his decision not to stand for re-election at…
8-K — Impact 2/10
Aug 24, 2026 SEC
Two insiders at Starling Oncology traded in opposite directions within a week: Director Brad Hively sold $1.95M worth…
CLUSTER — Impact 3/10
Aug 21, 2026 Insider
Hively Brad sold 298,853 shares
Director @ $6.51 ($1.9M)
Aug 17, 2026 SEC
A 10% owner of Starling Oncology bought $78K in shares open-market at $6.54, while selling a trivial $624. The net…
INSIDER-BUY — Impact 3/10
Aug 14, 2026 Insider
Chernett Jorey bought 12,000 shares
10%+ Owner @ $6.54 ($78.5K)
Aug 13, 2026 Insider
Chernett Jorey sold 100 shares
10%+ Owner @ $6.24 ($624.00)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
1,735,337 shares ($9.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
STLN Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 26, 2026
Earnings
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (“STLN”) (NASDAQ: STLN) a pioneer in value-based community oncology…
Oct 1, 2026
Press release
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community…
Aug 4, 2026
Listing
New Listing: STLN — Starling Oncology Institute, Inc. - Common Stock
Listed on exchange Q

SecBot reports

3 filings · 0 bullish · 0 bearish · 3 neutral
All STLN filing & press-release reports (3)